https://lumosdiagnostics.com/ 2024-08-19T23:01:53+00:00 1.00 https://lumosdiagnostics.com/products 2024-08-19T23:01:53+00:00 0.80 https://lumosdiagnostics.com/products/febridx 2024-08-19T23:01:53+00:00 0.80 https://lumosdiagnostics.com/products/viradx 2024-08-19T23:01:53+00:00 0.80 https://lumosdiagnostics.com/services 2024-08-19T23:01:53+00:00 0.80 https://lumosdiagnostics.com/services/assay-development 2024-08-19T23:01:53+00:00 0.80 https://lumosdiagnostics.com/services/readers 2024-08-19T23:01:53+00:00 0.80 https://lumosdiagnostics.com/services/app-cloud 2024-08-19T23:01:53+00:00 0.80 https://lumosdiagnostics.com/services/manufacturing 2024-08-19T23:01:53+00:00 0.80 https://lumosdiagnostics.com/services/medical-affairs 2024-08-19T23:01:53+00:00 0.80 https://lumosdiagnostics.com/services/quality-regulatory-affairs 2024-08-19T23:01:53+00:00 0.80 https://lumosdiagnostics.com/about/about-lumos 2024-08-19T23:01:53+00:00 0.80 https://lumosdiagnostics.com/about/team 2024-08-19T23:01:53+00:00 0.80 https://lumosdiagnostics.com/about/employment 2024-08-19T23:01:53+00:00 0.80 https://lumosdiagnostics.com/invest 2024-08-19T23:01:53+00:00 0.80 https://lumosdiagnostics.com/news 2024-08-19T23:01:53+00:00 0.80 https://lumosdiagnostics.com/contact 2024-08-19T23:01:53+00:00 0.80 https://lumosdiagnostics.com/team 2024-08-19T23:01:53+00:00 0.80 https://lumosdiagnostics.com/news-detail/q4-fy24-investor-webinar 2024-08-19T23:01:53+00:00 0.80 https://lumosdiagnostics.com/news-detail/lumos-diagnostics-quarterly-activity-statement-and-cash-flow-report-period-ended-30-june-2024 2024-08-19T23:01:53+00:00 0.80 https://lumosdiagnostics.com/news-detail/stockhead-air-supply-the-asx-medtechs-tackling-respiratory-illnesses 2024-08-19T23:01:53+00:00 0.80 https://lumosdiagnostics.com/documents/210604_LUM_GOV_PrivacyPolicy_Final.pdf 2024-05-12T07:45:36+00:00 0.80 https://lumosdiagnostics.com/products/febridx/usa 2024-08-19T23:01:53+00:00 0.64 https://lumosdiagnostics.com/products/febridx/rest-of-world 2024-08-19T23:01:53+00:00 0.64 https://lumosdiagnostics.com/documents/PM-169.2-ViraDx-IFU.pdf 2024-05-12T07:45:38+00:00 0.64 https://lumosdiagnostics.com/documents/PM-168.1-ViraDx-QRI.pdf 2024-05-12T07:45:31+00:00 0.64 https://lumosdiagnostics.com/documents/PM-231.2-ViraDx-Sell-Sheet-US.pdf 2024-05-12T07:45:17+00:00 0.64 https://lumosdiagnostics.com/documents/PM-223.1_ViraDx-US-Fast-Facts.pdf 2024-05-12T07:45:32+00:00 0.64 https://lumosdiagnostics.com/documents/PM-242.1_ViraDx-FAQs.pdf 2024-05-12T07:45:31+00:00 0.64 https://lumosdiagnostics.com/documents/PM-500-ViraDx-Fact-Sheet-for-Patients.pdf 2024-05-12T07:45:27+00:00 0.64 https://lumosdiagnostics.com/documents/PM-501-ViraDx-Fact-Sheet-for-Healthcare-Providers.pdf 2024-05-12T07:45:16+00:00 0.64 https://lumosdiagnostics.com/news-detail/febridx-now-available-to-health-care-practitioners-in-belgium 2024-08-19T23:01:53+00:00 0.64 https://lumosdiagnostics.com/news-detail/lumos-diagnostics-expands-distribution-partnership-with-regional-health-care-group-henry-scheins-medical-business-in-australia-and-new-zealand-for-febridx 2024-08-19T23:01:53+00:00 0.64 https://lumosdiagnostics.com/news-detail/hologic-enables-maiden-net-free-cash-flow 2024-08-19T23:01:53+00:00 0.64 https://lumosdiagnostics.com/news-detail/video-qanda-with-paul-kase-svp-commercial-operations 2024-08-19T23:01:53+00:00 0.64 https://lumosdiagnostics.com/news-detail/lumos-receives-usdollar400k-phase-1-milestone-payment-from-hologic 2024-08-19T23:01:53+00:00 0.64 https://lumosdiagnostics.com/news-detail/new-febridx-study-journal-of-antimicrobial-chemotherapy 2024-08-19T23:01:53+00:00 0.64 https://lumosdiagnostics.com/news-detail/lumos-signs-major-development-and-ip-agreements-with-hologic 2024-08-19T23:01:53+00:00 0.64 https://lumosdiagnostics.com/news-detail/Quarterly-Interview-with-LDX-CEO-Doug-Ward 2024-08-19T23:01:53+00:00 0.64 https://lumosdiagnostics.com/news-detail/lumos-to-exhibit-at-2024-urgent-care-convention 2024-08-19T23:01:53+00:00 0.64 https://lumosdiagnostics.com/news-detail/new-febridx-study-published-in-peer-reviewed-journal-infectious-diseases-and-clinical-microbiology 2024-08-19T23:01:53+00:00 0.64 https://lumosdiagnostics.com/news-detail/lumos-appoints-henry-schein-as-us-distributor-for-febridx-r 2024-08-19T23:01:53+00:00 0.64 https://lumosdiagnostics.com/news-detail/cbs-news-cdc-warns-overuse-of-antibiotics-may-cause-antimicrobial-resistant-infections 2024-08-19T23:01:53+00:00 0.64 https://lumosdiagnostics.com/news-detail/us-fda-grants-emergency-use-authorization-for-viradx 2024-08-19T23:01:53+00:00 0.64 https://lumosdiagnostics.com/news-detail/usa-today-not-if-but-when-antibiotic-resistance-poses-existential-threat-for-modern-medicine 2024-08-19T23:01:53+00:00 0.64 https://lumosdiagnostics.com/news-detail/lumos-receives-us-fda-clearance-for-febriDx 2024-08-19T23:01:53+00:00 0.64 https://lumosdiagnostics.com/news-detail/lumos-diagnostics-appoints-doug-ward-as-ceo 2024-08-19T23:01:53+00:00 0.64 https://lumosdiagnostics.com/news-detail/economic-evaluation-of-lumos-diagnostics-febridx-point-of-care-test-highlights-2-5-billion-in-potential-u-s-healthcare-cost-savings-annually 2024-08-19T23:01:53+00:00 0.64 https://lumosdiagnostics.com/documents/PM-063.1%20FebriDxUS%20QRI.pdf 2024-05-12T07:45:37+00:00 0.51 https://lumosdiagnostics.com/documents/PM-116.0-FebriDx-UrgentCare-US.pdf 2024-05-12T07:45:19+00:00 0.51 https://lumosdiagnostics.com/documents/PM-127.1%20FebriDx%20IFU-US.pdf 2024-05-12T07:45:24+00:00 0.51 https://lumosdiagnostics.com/documents/SDS-00013.2%20USA%20FebriDx%20Test.pdf 2024-05-12T07:45:12+00:00 0.51 https://lumosdiagnostics.com/documents/PM-079.1%20FebriDx%20US%20External%20Controls%20IFU.pdf 2024-05-12T07:45:32+00:00 0.51 https://lumosdiagnostics.com/documents/PM-033.7%20FebriDxOUS-QRI-ENG%20081023.pdf 2024-05-12T07:45:25+00:00 0.51 https://lumosdiagnostics.com/documents/SDS-00001.2FDX%20FebriDx%20Test.pdf 2024-05-12T07:45:14+00:00 0.51 https://lumosdiagnostics.com/documents/PM-064.5%20FebriDx%20IFU%20AUS.pdf 2024-05-12T07:45:24+00:00 0.51 https://lumosdiagnostics.com/documents/PM-108.4%20FebriDx%20IFU%20Canada.pdf 2024-05-12T07:45:13+00:00 0.51 https://lumosdiagnostics.com/documents/PM-002.12%20FebriDx%20IFU%20CE%20MARK.pdf 2024-05-12T07:45:26+00:00 0.51